On Friday, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) was 7.19% up from the session before settling in for the closing price of $8.35. A 52-week range for EYPT has been $5.86 – $30.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 69.47%. When this article was written, the company’s average yearly earnings per share was at -22.02%. With a float of $47.25 million, this company’s outstanding shares have now reached $49.04 million.
Let’s determine the extent of company efficiency that accounts for 121 employees. In terms of profitability, gross margin is 91.48%, operating margin of -255.88%, and the pretax margin is -226.38%.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward EyePoint Pharmaceuticals Inc stocks. The insider ownership of EyePoint Pharmaceuticals Inc is 11.72%, while institutional ownership is 104.20%. The most recent insider transaction that took place on Oct 23 ’24, was worth 673,355. Before that another transaction happened on Oct 14 ’24, when Company’s Former Director proposed sale 36,975 for $8.92, making the entire transaction worth $329,817.
EyePoint Pharmaceuticals Inc (EYPT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -22.02% per share during the next fiscal year.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
You can see what EyePoint Pharmaceuticals Inc (EYPT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Looking closely at EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), its last 5-days average volume was 1.52 million, which is a jump from its year-to-date volume of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 13.37%. Additionally, its Average True Range was 0.92.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 23.54%, which indicates a significant increase from 17.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.02% in the past 14 days, which was higher than the 87.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.77, while its 200-day Moving Average is $13.45. However, in the short run, EyePoint Pharmaceuticals Inc’s stock first resistance to watch stands at $9.44. Second resistance stands at $9.94. The third major resistance level sits at $10.56. If the price goes on to break the first support level at $8.33, it is likely to go to the next support level at $7.71. Should the price break the second support level, the third support level stands at $7.21.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
There are 68,251K outstanding shares of the company, which has a market capitalization of 654.74 million. As of now, sales total 46,020 K while income totals -70,800 K. Its latest quarter income was 10,520 K while its last quarter net income were -29,360 K.
